Correlation Engine 2.0
Clear Search sequence regions

  • apheresis (1)
  • cell count (2)
  • child (1)
  • children (4)
  • cyclams (2)
  • drug reactions (2)
  • humans (1)
  • japan (5)
  • patients (7)
  • plerixafor (10)
  • pyrexia (1)
  • research (1)
  • sign (1)
  • stem cell (3)
  • Sizes of these terms reflect their relevance to your search.

    Plerixafor is approved in Japan for hematopoietic stem cell mobilization prior to autologous transplant, but limited data are available on the use in children. This study evaluates the safety and effectiveness of plerixafor in Japanese children aged <15 years. A multicenter, post-marketing surveillance study was conducted in Japan to evaluate the safety and effectiveness of plerixafor in routine clinical practice. This subgroup analysis examined the safety and effectiveness of plerixafor administered as a once-daily, subcutaneous injection in children aged <15 years. The primary effectiveness outcome was the proportion of patients with 2 × 106 cells CD34+ cells/kg collected via apheresis within 4 days. Eighteen patients with solid tumors were included in this analysis; (median age 6.0 years, range, 1-13 years). In addition to granulocyte colony-stimulating factor, all patients had received chemotherapy immediately prior to plerixafor administration. The mean (SD) daily dose of plerixafor was 0.24 (0.01) mg/kg. Seven of the 18 patients (38.9%) developed adverse drug reactions (ADRs), all occurring in patients aged ≥6 years and weighing ≥16 kg. The most common ADRs were pyrexia (n = 4), vomiting (n = 3), nausea (n = 2), and abdominal pain (n = 2). Twelve patients (66.7%) achieved a CD34+ cell count ≥2 × 106 cells/kg within 4 days after the start of plerixafor administration. The results provide an encouraging sign that plerixafor 0.24 mg/kg may be safe and effective in pediatric patients in routine clinical practice in Japan, but further research in larger studies is needed. © 2022 The Authors. Pediatrics International published by John Wiley & Sons Australia, Ltd on behalf of Japan Pediatric Society.


    Hiroaki Goto, Rie Kanamori, Satoshi Nishina, Takashi Seto. Plerixafor stem cell mobilization in Japanese children: A post-marketing study. Pediatrics international : official journal of the Japan Pediatric Society. 2022 Jan;64(1):e15106

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 35396889

    View Full Text